Abstract Number: 0887 • ACR Convergence 2021
Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
Background/Purpose: Cognitive dysfunction (CD) is a common manifestation of systemic lupus erythematosus (SLE) which can have detrimental consequences for those affected. To date, no treatments…Abstract Number: 0988 • ACR Convergence 2021
Risk Prediction Models for Incident Systemic Lupus Erythematosus Using Lifestyle/Environmental Risk Factors and a Genetic Risk Score
Background/Purpose: The identification of lifestyle/environmental and genetic factors, influencing SLE risk introduces the potential to develop risk prediction models. We examined SLE risk prediction incorporating…Abstract Number: 1152 • ACR Convergence 2021
A Follow-Up Evaluation of a Longstanding Telephone Peer Counseling Service for People with Systemic Lupus Erythematosus and Their Loved Ones
Background/Purpose: With technology rapidly evolving, studies still reinforce the value of telephone peer support for people living with chronic illness. A follow-up evaluation was conducted…Abstract Number: 1267 • ACR Convergence 2021
Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
Background/Purpose: Emergency department (ED) utilization is associated with worse quality of care and health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE). While frailty…Abstract Number: 1283 • ACR Convergence 2021
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
Background/Purpose: Glucocorticoids (GC) play an important role in rapid systemic lupus erythematosus (SLE) symptom relief. However, chronic GC use increases organ damage risk; and treatment…Abstract Number: 1300 • ACR Convergence 2021
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
Background/Purpose: We have previously shown that prolonged clinical remission for ≥10 years is associated with significantly less damage accrual in inception patients with systemic lupus…Abstract Number: 1461 • ACR Convergence 2021
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
Background/Purpose: In the BLISS-LN trial (GSK Study BEL114054; NCT01639339), the administration of belimumab (BEL), a B-lymphocyte stimulator antagonist, resulted in improved renal outcomes in patients…Abstract Number: 1494 • ACR Convergence 2021
Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon
Background/Purpose: Interferon (IFN)-α contributes to susceptibility and severe manifestations in systemic lupus erythematosus (SLE). The PRKG1 rs7897633 variant has been previously identified as the top…Abstract Number: 1595 • ACR Convergence 2021
Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
Background/Purpose: Opportunities for community mobility, which reflects both physical mobility and social participation, during the COVID-19 pandemic have been limited and may have been related…Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…Abstract Number: 1752 • ACR Convergence 2021
Efficacy of Voclosporin in Recent Onset Lupus Nephritis
Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adults with active lupus nephritis (LN) in combination with background immunosuppressive therapy.…Abstract Number: 1770 • ACR Convergence 2021
Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic
Background/Purpose: There is heightened interest in the use of mesenchymal stromal cells (MSCs) for the treatment of autoimmune diseases. There are a number of reports…Abstract Number: 0131 • ACR Convergence 2021
Association of Numeracy with Medication Non-Adherence in Systemic Lupus Erythematosus
Background/Purpose: Over 33% of U.S. adults have limited health literacy or numeracy. Limited health literacy and numeracy have been associated with higher disease activity and…Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 150
- Next Page »